登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《LANCET，3月17日，Prevention of SARS-CoV-2 infection in patients with decompensated cirrhosis》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-03-18

  • Prevention of SARS-CoV-2 infection in patients with decompensated cirrhosis

    Yong Xiao

    Hong Pan

    Qian She

    Fen Wang

    Mingkai Chen

    Published:March 17, 2020DOI:https://doi.org/10.1016/S2468-1253(20)30080-7

    We read the Comment by Chao Zhang and colleagues1 in The Lancet Gastroenterology & Hepatology on liver injury in coronavirus disease 2019 (COVID-19) with great interest. Given that patients with decompensated cirrhosis have a higher risk of, and mortality from, infection, preventing infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in this patient population is a challenging task.2 We provide our experience of COVID-19 prevention in patients with decompensated cirrhosis in Wuhan, China.

  • 原文来源：https://www.thelancet.com/journals/langas/article/PIIS2468-1253(20)30080-7/fulltext
27浏览量
原文链接
相关报告

  • 《LANCET，3月23日，SARS-CoV-2: virus dynamics and host response》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-24
    • SARS-CoV-2: virus dynamics and host response Yu Chen Lanjuan Li Published:March 23, 2020DOI:https://doi.org/10.1016/S1473-3099(20)30235-8 Since December, 2019, coronavirus disease 2019 (COVID-19) has affected more than 100?000 patients globally.1 COVID-19 is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has a case-fatality rate of 2·3%, with higher rates among elderly patients and patients with comorbidities.2 Person-to-person transmission is efficient, with multiple clusters reported. Clinically, patients with COVID-19 present with respiratory symptoms, which is very similar to the presentation of other respiratory virus infections.
    144浏览量
    原文链接

  • 《LANCET，5月18日，Detection of IgM and IgG antibodies against SARS-CoV-2 in patients with autoimmune diseases》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-05-19
    • Detection of IgM and IgG antibodies against SARS-CoV-2 in patients with autoimmune diseases Jialin Teng † Jin Dai † Yutong Su † Zhuochao Zhou Huihui Chi Liyan Wan Published:May 18, 2020DOI:https://doi.org/10.1016/S2665-9913(20)30128-4 Detection of IgM and IgG antibodies against SARS-CoV-2 in patients with autoimmune diseases In December, 2019, an outbreak of the novel coronavirus (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19) occurred in Wuhan, China,1 and soon spread all over the world. Rapid and accurate diagnosis of SARS-CoV-2 infection is the cornerstone of all efforts to stem its advancement. Molecular detection via RT-PCR can result in falsely negative results due to the low viral loads in a sample. Serological methods are being developed and have proven to be a useful supplementary approach in confirming SARS-CoV-2 infection.2 The US Food and Drug Administration has issued numerous Emergency Use Authorisations, including serological tests; however, the potential for cross-reactivity with antibodies present in the sera of patients with other diseases remains largely unknown. Cross-reactivity of antibodies against SARS-CoV-2 with antibodies against other coronaviruses, such as SARS-CoV, has been shown.3 In addition, cross-reactivity has been observed from autoantibodies in serum samples from patients with autoimmune disease when testing for SARS-CoV,4 which shares high sequence identity with SARS-CoV-2. As such, we wanted to determine whether autoantibodies interfere with detection of SARS-CoV-2 antibodies.
    25浏览量
    原文链接